Answer
Yes, ipilimumab (Yervoy) monotherapy can cause life-threatening skin reactions including Stevens–Johnson syndrome or toxic epidermal necrolysis, for which treatment must be permanently discontinued.
Sources for this answer
- YERVOY 5 mg/ml concentrate for solution for infusionBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.2 Posology and method of administration · Version 46Document updated
Sources checked